In 2022, the U.S. states with the highest rates of Lyme disease were Rhode Island, Vermont, and Maine. However, the states with the highest total number of Lyme disease cases were New York, Pennsylvania, and New Jersey. That year, there were a total of 2,653 cases of Lyme disease in the state of Maine, with an incidence rate of 192.6 per 100,000 population.

What is Lyme disease? Lyme disease is caused by bacteria usually transmitted to humans through the bite of a tick. Lyme disease is the most common vector-borne disease in the United States, however it is much more prevalent in some states than others, with the upper Midwest and the Northeastern states most at risk. Symptoms of Lyme disease can vary and usually come in stages but may include a rash, fever, headache, stiffness in the joints, tiredness, and muscle aches and pains. Lyme disease is usually treated with antibiotics. In 2022, funding for Lyme disease from the National Institutes of Health (NIH) totaled around 50 million U.S. dollars.

Trends in Lyme disease Although the number of Lyme disease cases per year fluctuates, over the past couple decades, the number of Lyme disease cases in the United States has steadily increased. Between 1996 and 2022, the highest number of Lyme disease cases was in the year 2022 when over 62,500 cases were reported. The lowest number reported during this period was in 1997, with around 12,800 cases. Cases of Lyme disease are much more common in the summer months of June and July as this is when people are most likely to encounter ticks. The risk of Lyme disease is expected to increase in the future as climate change contributes to an expanded habitat for ticks.

In 2022, New York had 16,798 cases of Lyme disease. That year, there were a total of 62,519 cases of Lyme disease in the United States. Lyme disease is a bacterial infection spread by ticks. Lyme disease is the most commonly reported vector-borne illness in the United States. This statistic displays the number of confirmed Lyme disease cases in each state in the United States in 2022.

In 2022, the incidence rate of Lyme disease was around 19 per 100,000 population. Lyme disease is a bacterial infection spread by ticks. It is the most commonly reported vector-borne illness in the United States. This statistic displays the incidence rates of confirmed Lyme disease cases in the United States from 1996 to 2022, per 100,000 persons.

From 2008 to 2022, there were around 87,802 cases of Lyme disease with an onset in July. Lyme disease is a bacterial infection transmitted by ticks to humans. It is the most commonly reported vector-borne illness in the United States. This statistic displays the number of cases of Lyme disease in the U.S. from 2008 to 2022, by month.

Access the data here: https://www.epa.gov/climate-indicators/climate-change-indicators-lyme-diseaseMulti-decadal analysis of changes in the incidence of Lyme disease, by state

Data for "By-degree Health and Economic Impacts of Lyme Disease, Eastern and Midwestern United States", published March 2024. The datasets show cases by state, fips code, case status, sex, age (by 5-year increments), and frequency. Citation information for this dataset can be found in Data.gov's References section.

NNDSS - Table II. Lyme disease to Meningococcal - 2016. In this Table, provisional* cases of selected† notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. Case counts for reporting year 2016 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. † Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions. § Data for meningococcal disease, invasive caused by serogroups ACWY; serogroup B; other serogroup; and unknown serogroup are available in Table I.

This map shows the Lyme Disease incidence rate per 100,000 by county. Counties are shaded based on quartile distribution. The lighter shaded counties have lower incidence rates of Lyme Disease. The darker shaded counties have higher incidence rates of Lyme Disease. New York State Community Health Indicator Reports (CHIRS) were developed in 2012, and are updated annually to consolidate and improve data linkages for the health indicators included in the County Health Assessment Indicators (CHAI) for all communities in New York. The CHIRS present data for more than 300 health indicators that are organized by 15 different health topics. Data if provided for all 62 New York State counties, 11 regions (including New York City), the State excluding New York City, and New York State. For more information, check out: http://www.health.ny.gov/statistics/chac/indicators/. The "About" tab contains additional details concerning this dataset.

The California Department of Public Health, Vector-Borne Disease Section (CDPH-VBDS) and its partner agencies collect and test ticks for tick-borne pathogens as part of a statewide vector-borne disease surveillance program. CDPH also collects information on reported confirmed human Lyme disease cases in California.

In California, the western blacklegged tick (Ixodes pacificus) is the vector (or carrier) of Lyme disease caused by the agent Borrelia burgdorferi. This story map displays county-level summaries of blacklegged tick collections since 1985, Borrelia burgdorferi testing since 1985, and the number of reported confirmed human Lyme disease cases by county of residence from 20010 to 2019.

_

Layers:

County summaries of Ixodes pacificus collections and testing in California from 1985-2019: This layer provides county-level summaries of western blacklegged tick collections and Borrelia burgdorferi testing results from 1985 to 2019. Results for the nymphal and adult tick stages are provided. Note that nymphal ticks may pose a higher Lyme disease infection risk to humans than adult ticks.

Ixodes pacificus collection locations, 1985 - 2019: This layer shows where western blacklegged ticks have been collected throughout the state.

County Ixodes pacificus collection totals, 1985 - 2019: This layers provides a county-level summary of the total number of Ixodes pacificus collected from 1985 - 2018.

Lyme Disease Incidence, 2010 - 2019: This layer presents the number of confirmed human Lyme disease cases per 100,000 person-years by county. Click on a county to view the incidence for that county.

_

Notes:

• Since tick collection is not done uniformly throughout the state, absence of tick collection or Borrelia burgdorferi-positive ticks in a given area may indicate lack of surveillance data; it does not mean that ticks or infected ticks are absent.
• Data on this map represent ticks collected by the California Department of Public Health, local mosquito and vector control agencies, and other public agencies. Data for ticks independently tested by local mosquito and vector control agencies may not be included on this map.

In the period 2008 to 2022, there were around 290 thousand Lyme disease cases among white people in the United States. This statistic shows the number of Lyme disease cases in the United States in the period 2008 to 2022, by race

NNDSS - Table II. Lyme disease to Meningococcal - 2016. In this Table, provisional* cases of selected† notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

• Case counts for reporting year 2016 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. † Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions. § Data for meningococcal disease, invasive caused by serogroups ACWY; serogroup B; other serogroup; and unknown serogroup are available in Table I.

NNDSS - Table II. Lyme disease to Meningococcal - 2014In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. ��� Data for meningococcal disease, invasive caused by serogroups A, C, Y, & W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

NNDSS - Table II. Lyme disease to Meningococcal - 2014In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. ��� Data for meningococcal disease, invasive caused by serogroups A, C, Y, & W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

IntroductionLyme disease (LD) incidence in the United States is highly regional, with most cases occurring in 16 high-incidence jurisdictions. LD incidence and severity of disease have been found to vary by race. This study describes racial differences in knowledge, attitudes toward vaccination, and risk practices related to LD.MethodsFour web-based surveys were conducted with adults and caregivers of children in high-incidence jurisdictions and 10 states neighboring them. Respondents were recruited via an established online panel to represent the general population. Self-reported race was pooled into 3 categories: ‘White’, ‘Black or African American’, and ‘Other’ for analysis. Analyses were conducted separately for each jurisdiction (high-incidence vs. neighboring) and respondent type (adult vs. caregiver).ResultsThe final sample across all surveys included 2,249 respondents who identified as White, 493 respondents who identified as Black or African American, and 674 respondents of other races. White respondents were older, had higher incomes, and were likelier to live in small cities and rural areas. Though attitudes toward vaccination in general were similar between racial categories, when differences were present, Black respondents were more likely to have concerns about vaccines than White respondents. In all surveys, White respondents engaged in more outdoor activities than Black respondents and performed these activities more often. However, both White adults and caregivers in high-incidence jurisdictions were significantly less likely to have occupations with primarily outdoor work than corresponding respondents in other racial groups. Black respondents also had lower knowledge about LD than White respondents across all surveys. This difference was significant after adjusting for state incidence level and urbanicity.ConclusionThere are some racial differences in knowledge, attitudes, and practices around LD, with White respondents reported having higher knowledge of LD, less concerns about vaccines, and higher frequency of risk practices. These differences might contribute to racial disparities in LD outcomes.

To facilitate the public health and research community's access to NNDSS data on Lyme disease, CDC has developed a public use dataset. Based on reports submitted to CDC, this dataset provides the number of confirmed cases by county for the years 1992���2011, in four 5���year intervals. County tabulation is by American National Standard Institute (ANSI) [formerly Federal Information Processing Standard (FIPS)] codes. County codes of "0" represent "unknown" county of residence within each state. More recent county-level case counts are not publicly available at this time.

Analysis of ‘NNDSS - Table II. Lyme disease to Meningococcal’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://catalog.data.gov/dataset/d63197f6-5a0e-41a1-9ad4-f6fe03e0849b on 26 January 2022.

--- Dataset description provided by original source is as follows ---

NNDSS - Table II. Lyme disease to Meningococcal - 2015.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed.The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. �� Data for meningococcal disease, invasive caused by serogroups ACWY; serogroup B; other serogroup; and unknown serogroup are available in Table I.

--- Original source retains full ownership of the source dataset ---

From the period 2008 to 2022, the incidence rate of Lyme disease among males in the United States was highest among those aged 65 to 69 years. This statistic shows the incidence rate of Lyme disease in the United States in the period 2008 to 2022, by age and gender.

In 2022, there were 62,551 reported cases of Lyme disease in the United States, an increase from 34,945 cases in 2019. This graph shows the number of tick-borne disease cases reported in the U.S. from 2019 to 2022, by disease.

The causative bacterium of Lyme disease, Borrelia burgdorferi, expanded from an undetected human pathogen into the etiologic agent of the most common vector-borne disease in the United States over the last several decades. Systematic field collections of the tick vector reveal increases in the geographic range and population size of B. burgdorferi that coincided with increases in human Lyme disease incidence across New York State. Here we investigate the impact of environmental features on the population dynamics of B. burgdorferi. Analytical models developed using field collections of nearly 19,000 nymphal Ixodes scapularis and spatially- and temporally-explicit environmental features accurately explained the variation of B. burgdorferi population sizes across space and time. Importantly, the model identified environmental features that can be used to predict the biogeographical patterns of B. burgdorferi-infected ticks into future years and in previously unsampled areas. Forecasting the distribution and abundance of a pathogen at fine geographic scales offers a powerful strategy to mitigate a serious public health threat.

In 1996, there were 16,455 new cases of Lyme disease in the United States. In 2022, the number of new cases stood at 62,551. This statistic shows the number of new cases of Lyme disease in the U.S. from 1996 to 2022.